Why the World’s Largest Food Company Saw Promise in a Peanut Allergy Drug

In January of 2020, the first drug for peanut allergies, <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treatment-peanut-allergy-children" rel="noopener ugc nofollow" target="_blank">Palforzia</a>, was approved by the FDA. It was the first and only FDA-approved treatment to help reduce the severity and frequency of peanut allergies, which increased<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477625/" rel="noopener ugc nofollow" target="_blank"> 3.5-fold</a> over the past two decades reaching 1.4–2% of the population in Europe and the United States. The company that made the drug was bought by Nestlé, the world’s largest publicly held food corporation, later that same year. The move made sense for Nestlé, as preventing such a common food allergy for the world’s largest food company meant more revenue. Couple this with the fact that the drug was hella expensive and you have a winning formula. <a href="https://medium.com/wise-well/why-the-worlds-largest-food-company-saw-promise-in-a-peanut-allergy-drug-50b20722e7ea">Visit Now</a>